Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Outcomes Among Patients Treated With Immune Checkpoint Inhibitors in the Inpatient Setting
09/30/2022

Marta Rybczynski

Marta Rybczynski
Clinical outcomes from a multi-institutional study analyzing patient outcomes following inpatient immune checkpoint inhibitor therapy may “give clinicians pause” when considering inpatient immune checkpoint inhibitor use, according to a study...
Clinical outcomes from a multi-institutional study analyzing patient outcomes following inpatient immune checkpoint inhibitor therapy may “give clinicians pause” when considering inpatient immune checkpoint inhibitor use, according to a study...
Clinical outcomes from a...
09/30/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Pathway Compliance Linked to First-Line Treatment Regimen
09/30/2022

Craig Ostroff

Craig Ostroff
Pathway compliance was observed in almost two-thirds of cases among patients with metastatic disease who were treated in the first-line setting, according to a presentation at the 2022 ASCO Quality Care Symposium. Due to increasing health...
Pathway compliance was observed in almost two-thirds of cases among patients with metastatic disease who were treated in the first-line setting, according to a presentation at the 2022 ASCO Quality Care Symposium. Due to increasing health...
Pathway compliance was observed...
09/30/2022
Journal of Clinical Pathways
Conference Coverage
Evaluating Cost Savings of Collaborative Cancer-Patient Navigation Program Compared to Embedded Programs
09/30/2022

Craig Ostroff

Craig Ostroff
Cancer-patient navigation programs tend to reduce total costs of care and improve outcomes. This study, presented at the 2022 ASCO Quality Care Symposium, explored whether an independent cancer-patient navigation program in collaboration with...
Cancer-patient navigation programs tend to reduce total costs of care and improve outcomes. This study, presented at the 2022 ASCO Quality Care Symposium, explored whether an independent cancer-patient navigation program in collaboration with...
Cancer-patient navigation...
09/30/2022
Journal of Clinical Pathways
Conference Coverage
Assessing the Impact of COVID-19 on Prescribing Patterns in Multiple Myeloma
09/30/2022

Marta Rybczynski

Marta Rybczynski
While the total number of new therapy starts in multiple myeloma (MM) decreased during COVID-19, the rate of new starts for both intravenous and oral therapies in MM significantly increased, according to study findings presented at the 2022...
While the total number of new therapy starts in multiple myeloma (MM) decreased during COVID-19, the rate of new starts for both intravenous and oral therapies in MM significantly increased, according to study findings presented at the 2022...
While the total number of new...
09/30/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
PRO-Based Symptom Management Shows Links to Improved Clinical Outcomes
09/30/2022

Craig Ostroff

Craig Ostroff
Randomized controlled trials at academic medical centers have shown an improvement in clinical outcomes when utilizing patient-reported outcome-based symptom management solutions, according to a presentation at the 2022 ASCO Quality Care...
Randomized controlled trials at academic medical centers have shown an improvement in clinical outcomes when utilizing patient-reported outcome-based symptom management solutions, according to a presentation at the 2022 ASCO Quality Care...
Randomized controlled trials at...
09/30/2022
Journal of Clinical Pathways
Conference Coverage
EFI an Objective, Standardized Approach Option to Frailty in Colorectal Cancer
09/30/2022
Traditional frailty indices are not widely utilized in clinical oncology. According to a presentation at the 2022 ASCO Quality Care Symposium, an EFI created from electronic medical records can be utilized as an objective, standardized...
Traditional frailty indices are not widely utilized in clinical oncology. According to a presentation at the 2022 ASCO Quality Care Symposium, an EFI created from electronic medical records can be utilized as an objective, standardized...
Traditional frailty indices are...
09/30/2022
Journal of Clinical Pathways
Conference Coverage
Gold Nanoparticles’ Role in Photodynamic Therapy for Cancer Treatment
07/22/2022

Ellen Kurek

Ellen Kurek
Researchers highlight the importance of health care providers’ awareness of advancements and utility of photodynamic therapy as a way to provide a less invasive, more effective way to treat patients with cancer.
Researchers highlight the importance of health care providers’ awareness of advancements and utility of photodynamic therapy as a way to provide a less invasive, more effective way to treat patients with cancer.
Researchers highlight the...
07/22/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Standardizing Utilization of Biosimilars in Oncology
07/06/2022

Ellen Kurek

Ellen Kurek
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent...
07/06/2022
Journal of Clinical Pathways
Conference Coverage
Efficacy of Virtual Live Education on the Knowledge of Gynecologists Caring for Patients With Ovarian Cancer
06/22/2022
Vanessa Carranza, PharmD, created an educational initiative that focused on obstetricians, gynecologists, and other health care professionals, aiming to evaluate their knowledge on PARP inhibitors in ovarian cancer, ability to identify those...
Vanessa Carranza, PharmD, created an educational initiative that focused on obstetricians, gynecologists, and other health care professionals, aiming to evaluate their knowledge on PARP inhibitors in ovarian cancer, ability to identify those...
Vanessa Carranza, PharmD,...
06/22/2022
Journal of Clinical Pathways
Conference Coverage
Efficacy of Teclistamab vs Real-World Treatments for Patients with Triple-Class Exposed, Relapsed/Refractory Multiple Myeloma
06/22/2022

Ellen Kurek

Ellen Kurek
A study presented at the 2022 ASCO Annual Meeting evaluated the comparative effectiveness of teclistamab vs treatment regimens using an external control arm from a real-world database, addressing the absence of a control arm in MajesTEC-1.
A study presented at the 2022 ASCO Annual Meeting evaluated the comparative effectiveness of teclistamab vs treatment regimens using an external control arm from a real-world database, addressing the absence of a control arm in MajesTEC-1.
A study presented at the 2022...
06/22/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use